"Cytogenetic Response in Chronic Myeloid Leukaemia Patients Treated with Imatinib Mesylate Homolog-Drugs: 6 Year’s Transitional Study"
written by Najmaddin Khoshnaw, Bassam Francis, Banaz M. Safar, Salim S. Mahmood, Beston F. Nore,
published by Journal of Cancer Therapy, Vol.5 No.5, 2014
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] Effects of Nilotinib on Platelet Function in Patients with Chronic Myeloid Leukemia in Chronic Phase
Leukemia Research Reports, 2018
[2] Differential effects of tyrosine kinase inhibitors in haemostasis, thrombosis and inflammation
2018
[3] Lung cancer incidence in Sulaimani province during (2011–2015)
2017
[4] On the use of substandard medicines in hematology: An emerging concern in the Middle East and North Africa region
European Journal of Internal Medicine, 2017
[5] Rebuttal and response to:“The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient …
Leukemia & Lymphoma, 2015
[6] Rebuttal and response to:“The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?” by Ahmet Emre Eskazan, Muhlis Cem Ar and Teoman Soysal
Leukemia & lymphoma, 2015
[7] Rebuttal and response to:“The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient …
Drug and Chemical Toxicology, 2015
[8] Patterns of cancer in Kurdistan-results of eight years cancer registration in Sulaymaniyah Province-Kurdistan-Iraq
2015
[9] Rebuttal and response to:" The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient …
2015
[10] Generics in chronic myeloid leukemia: current arguments for and against and the established evidence
Expert review of hematology, 2014